213 related articles for article (PubMed ID: 17287964)
1. [Therapy of follicular lymphoma].
Buske C; Unterhalt M; Hiddeman W
Internist (Berl); 2007 Apr; 48(4):372-81. PubMed ID: 17287964
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of mantle cell lymphoma].
Dreyling M; Unterhalt M; Weigert O; Hiddemann W
Internist (Berl); 2007 Apr; 48(4):382-8. PubMed ID: 17308912
[TBL] [Abstract][Full Text] [Related]
3. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.
Morschhauser F; Radford J; Van Hoof A; Botto B; Rohatiner AZ; Salles G; Soubeyran P; Tilly H; Bischof-Delaloye A; van Putten WL; Kylstra JW; Hagenbeek A
J Clin Oncol; 2013 Jun; 31(16):1977-83. PubMed ID: 23547079
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
5. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
[TBL] [Abstract][Full Text] [Related]
6. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.
Zinzani PL; d'Amore F; Bombardieri E; Brammer C; Codina JG; Illidge T; Jurczak W; Linkesch W; Morschhauser F; Vandenberghe E; Van Hoof A
Eur J Cancer; 2008 Feb; 44(3):366-73. PubMed ID: 18194857
[TBL] [Abstract][Full Text] [Related]
7. [Monoclonal antibody treatment of malignant lymphoma].
Buske C; Dreyling M; Unterhalt M; Hiddemann W
Internist (Berl); 2004 Dec; 45(12):1370-7. PubMed ID: 15517123
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
[TBL] [Abstract][Full Text] [Related]
9. How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies?
Illidge T; Chan C
Leuk Lymphoma; 2008 Jul; 49(7):1263-73. PubMed ID: 18604715
[TBL] [Abstract][Full Text] [Related]
10. Transplantation strategies for patients with follicular lymphoma.
Buske C; Dreyling M; Unterhalt M; Hiddemann W
Curr Opin Hematol; 2005 Jul; 12(4):266-72. PubMed ID: 15928482
[TBL] [Abstract][Full Text] [Related]
11. Current management of follicular lymphomas.
Hiddemann W; Buske C; Dreyling M; Weigert O; Lenz G; Unterhalt M
Br J Haematol; 2007 Jan; 136(2):191-202. PubMed ID: 17073892
[TBL] [Abstract][Full Text] [Related]
12. Management options for follicular lymphoma: observe; R-CHOP; B-R; others?
McLaughlin P
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S91-5. PubMed ID: 22035757
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of aggressive lymphomas].
Gleissner B; Zwick C; Pfreundschuh M
Internist (Berl); 2007 Apr; 48(4):389-95. PubMed ID: 17361405
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy in follicular lymphoma: some like it hot….
Kersten MJ
Transfus Apher Sci; 2011 Apr; 44(2):173-8. PubMed ID: 21334979
[TBL] [Abstract][Full Text] [Related]
15. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
16. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
17. Investigational strategies in autologous stem cell transplantation for follicular lymphoma.
Weigert O; Dreyling M; Unterhalt M; Hiddemann W; Buske C
Curr Oncol Rep; 2006 Sep; 8(5):368-75. PubMed ID: 16901398
[TBL] [Abstract][Full Text] [Related]
18. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Witzig TE
Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
[TBL] [Abstract][Full Text] [Related]
20. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
Witzig TE
Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
